Anita Chakraverty, Author at Labiotech.eu

About

Anita Chakraverty is a freelance medical journalist and science communicator. Outside work, she enjoys a good movie, long walks in the local woods, and trying to get into pretzel-like yoga poses.

Articles by Anita Chakraverty

News and Trends 2 Apr 2020

Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment

The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease, also known as Covid-19. The therapeutic mRNA would be delivered directly into the lungs of symptomatic patients via nebulizers with nanoparticle aerosols. The mRNA could […]

April 2, 2020 - 3 minutesmins - By Anita Chakraverty

moderna biontech personalized cancer vaccine

News and Trends 24 Mar 2020

Vaccitech’s Prostate Cancer Vaccine Shows Promise in Phase II

The UK immunotherapy company Vaccitech has announced promising initial results from a phase IIa trial of a therapeutic vaccine that could offer a new way to treat advanced prostate cancer. In the open-label trial, the University of Oxford spin-off enrolled 23 patients with advanced castration-resistant prostate cancer. The patients received the company’s viral vector vaccine […]

March 24, 2020 - 2 minutesmins - By Anita Chakraverty

News and Trends 18 Mar 2020

OncoOne Raises €13M Series A to Develop First-in-Class Cancer Treatments

Austrian startup OncoOne has closed its first round of venture capital funding after raising €13M to investigate a new treatment target against solid tumor cancers. Investment in the Series A funding included public grants from the Austrian Research Promotion Agency and the promotional bank of the Austrian federal government, the Austria Wirtschaftsservice Gesellschaft, along with […]

March 18, 2020 - 2 minutesmins - By Anita Chakraverty

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us